Tracy Wiczer

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute — United States

Medicine · Health Sciences

13h-index1.1kcitations36works3.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(29), Lymphoma Diagnosis and Treatment(11), Chronic Myeloid Leukemia Treatments(10), PI3K/AKT/mTOR signaling in cancer(8), Immunodeficiency and Autoimmune Disorders(5)

Publications36 total

Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate
Journal of Oncology Pharmacy Practice·2026
Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis
Blood·2025Open Access
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation
Leukemia·2024· 12 citedOpen Access
A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
Leukemia & lymphoma/Leukemia and lymphoma·2024· 1 citedOpen Access
Abstract 17859: Real World Cardiovascular Events With Next Generation Bruton's Tyrosine Kinase Inhibitors - An Updated Analysis
Circulation·2023
Abstract 13214: Arrhythmic Burden After Bruton's Tyrosine Kinase Inhibitor Initiation and Major Cardiovascular Events
Circulation·2023
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
JACC CardioOncology·2023· 95 citedOpen Access
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
Leukemia·2023Open Access
Evaluation of bleeding events in patients receiving acalabrutinib therapy
Leukemia·2023· 5 cited
Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
Blood Advances·2023· 6 citedOpen Access
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity
JAMA Oncology·2023· 27 citedOpen Access
Abstract 12000: Ventricular Arrhythmias and Sudden Death Events Following Acalabrutinib Therapy Initiation for Hematology Malignancies
Circulation·2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
Blood·2022· 68 citedOpen Access
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Journal of Hematology & Oncology·2022· 34 citedOpen Access
INCIDENT HYPERTENSION AND CLINICAL OUTCOMES AFTER ACALABRUTINIB INITIATION FOR B-CELL MALIGNANCIES
Journal of the American College of Cardiology·2022
MYOCARDIAL INJURY AFTER IBRUTINIB INITIATION FOR HEMATOLOGIC MALIGNANCIES
Journal of the American College of Cardiology·2022· 3 cited
Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy
Blood·2021· 6 cited
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2020· 5 cited
Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy
Blood·2020· 2 cited
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists
Blood Advances·2020· 23 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Kerry A. Rogers(25), Jennifer A. Woyach(25), John C. Byrd(21), Farrukh T. Awan(21), Seema A. Bhat(19), Daniel Addison(15), Adam S. Kittai(14), Michael R. Grever(13), Qiuhong Zhao(12), Patrick Ruz(9), Leylah Azali(9), Lindsay Rosen(9), Marilly Palettas(9), John Alan Gambril(8), Avirup Guha(7), Onaopepo Kola‐Kehinde(7), John C. Byrd(6), Lauren Levine(5), Kami J. Maddocks(5), Sujay Kalathoor(5)